Structure and function of programmed death (PD) molecules

Veterinary Immunology and Immunopathology

Volumn 134, Issue 1-2, 2010, Pages 33-38

  Folkl, A ^a   Bienzle, D ^a  

^a UNIVERSITY OF GUELPH   (Canada)

Author keywords

Apoptosis; B7; CD274; CD279; Chronic viral infection; Co stimulation; Immunodeficiency

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MEMBRANE PROTEIN; PROGRAMMED CELL DEATH 1; PROGRAMMED CELL DEATH LIGAND 1; T LYMPHOCYTE RECEPTOR; TYROSINE; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; CYTOKINE PRODUCTION; IMMUNOCOMPETENT CELL; IMMUNOLOGICAL TOLERANCE; LYMPHOCYTE PROLIFERATION; MACROPHAGE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; PROTEIN TARGETING; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ADAPTIVE IMMUNITY; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; HUMANS; LYMPHOCYTES; MACROPHAGES; MICE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; VIRUS DISEASES;

EID: 75749152896     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vetimm.2009.10.006     Document Type: Review

References (64)

1. Barber D.L., Wherry E.J., Masopust D., Zhu B., Allison J.P., Sharpe A.H., Freeman G.J., and Ahmed R. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 (2006) 682-687
2. Berger R., Rotem-Yehudar R., Slama G., Landes S., Kneller A., Leiba M., Koren-Michowitz M., Shimoni A., and Nagler A. Phase I safety and pharmacokinetic study of CT-011, a humanized antibody interacting with PD-1, in patients with advanced hematologic malignancies. Clin. Cancer Res. 14 (2008) 3044-3051
3. Blank C., Brown I., Marks R., Nishimura H., Honjo T., and Gajewski T.F. Absence of programmed death receptor 1 alters thymic development and enhances generation of CD4/CD8 double-negative TCR-transgenic T cells. J. Immunol. 171 (2003) 4574-4581
4. Butte M.J., Kier M.E., Phamduy T.B., Sharpe A.H., and Freeman G.J. PD-L1 interacts specifically with B7-1 to regulate T cell function. J. Immunol. 178 (2007) 111-122
5. Carreras J., Lopez-Guillermo A., Roncador G., Villamor N., Colomo L., Martinez A., Hamoudi R., Howat W.J., Montserrat E., and Campo E. High numbers of tumor-infiltrating programmed cell death 1-positive regulatory lymphocytes are associated with improved overall survival in follicular lymphoma. J. Clin. Oncol. February 17 (2009) 10.1200/JCO.2008.18.0513
6. Day C.L., Kaufmann D.E., Kiepiela P., Brown J.A., Moodley E.S., Reddy S., Mackey E.W., Miller J.D., Leslie A.J., et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 443 (2006) 350-354
7. Dong H., Zhu G., Tamada K., and Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat. Med. 5 (1999) 1365-1369
8. Dong H., and Chen X. Immunoregulatory role of B7-H1 in chronicity of inflammatory responses. Cell. Mol. Immunol. 3 (2006) 179-187
9. Dorn C., Froh M., Schuster K., Scholmerich J., Blank C., and Hellerbrand C. Protective effect of PD-L1/PD-1 in acute hepatic ischemia-reperfusion injury. J. Hepatol. 48 (2008) S66
10. Faas S.J., Giannoni M.A., Mickle A.P., Kiesecker C.L., Reed D.J., Wu D., Fodor W.L., Mueller J.P., Matis L.A., and Rother R.P. Primary structure and functional characterization of a soluble, alternatively spliced form of B7-1. J. Immunol. 164 (2000) 6340-6348
11. Fife B.T., Guleria I., Bupp M., Tang Q., Eagar T., Bour-Jordan H., Yagita H., Azuma M., Sayegh M.H., and Bluestone J. The programmed death-1 pd-1 pathway regulates peripheral T cell tolerance during autoimmune diabetes in nonobese diabetic NOD mice. Clin. Immunol. 123 (2007) S27
12. Fife B.T., and Bluestone J. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol. Rev. 224 (2008) 166-182
13. Franceschini D., Paroli M., Francavilla V., Videtta M., Morrone S., Labbadia G., Cerino A., Mondelli M.U., and Barnaba V. PD-L1 negatively regulates CD4+CD25+Foxp3+ Tregs by limiting STAT-5 phosphorylation in patients chronically infected with HCV. J. Clin. Invest. February 23 (2009) 10.1172/JCI36604 (pii: 36604)
14. Freeman G.J., Wherry E.J., Ahmed R., and Sharpe A.H. Reinvigorating exhausted HIV-specific T cells via PD-1-PD-1 ligand blockade. J. Exp. Med. 203 (2006) 2223-2227
15. Golden-Mason L., Palmer B., Klarquist J., Mengshol J.A., Castelblanco N., and Rosen H.R. Upregulation of PD-1 expression on circulating and intrahepatic hepatitis C virus-specific CD8+ T cells associated with reversible immune dysfunction. J. Virol. 81 (2007) 9249-9258
16. Greenwald R.J., Freeman G.J., and Sharpe A.H. The B7 family revisited. Annu. Rev. Immunol. 23 (2005) 515-548
17. Guleria I., Khosroshahi A., Ansari M.J., Habicht A., Azuma M., Yagita H., Noelle R.J., and Sayegh M.H. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J. Exp. Med. 202 (2005) 231-237
18. Hansen J.D., Du Pasquier L., Lefranc M.P., Lopez V., Benmansour A., and Boudinot P. The B7 family of immunoregulatory receptors: a comparative and evolutionary perspective. Mol. Immunol. 46 (2009) 457-472
19. Huang X., Chung C.S., Chen Y., and Ayala A. Sepsis induces elevated expression of inhibitory receptor PD-1 and its ligand PD-L1 on immune cells. Shock 25 (2006) S146
20. Huang X., Venet F., Wang Y.L., Lepape A., Swan R., Chen Y., Chun-shiang C., Monneret G., and Ayala A. PD-1 deficiency protects mice from the lethality of sepsis by balancing efficient pathogen clearance and inflammatory cytokine production. FASEB J. 22 (2008) 675
21. Iwai Y., Ishida M., Tanaka Y., Okazaki T., Honjo T., and Minato N. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U.S.A. 99 (2002) 12293-12297
22. Iwai Y., Terawaki S., and Honjo T. PD-1 blockade inhibits hematogenous spread of poorly immunogenic tumor cells by enhanced recruitment of effector T cells. Int. Immunol. 17 (2005) 133-144
23. Jeon D.H., Oh K., Oh B.C., Nam D.H., Kim C.H., Park H.B., Cho J., Lee J.R., Lee D.S., and Lee G. Porcine PD-L1: cloning, characterization, and implications during xenotransplantation. Xenotransplantation 14 (2007) 236-242
24. Jones R.G., Saibil S.D., Pun J.M., Elford A.R., Bonnard M., Pellegrini M., Arya S., Parsons M.E., Krawczyk C.M., Gerondakis S., Yeh W.C., Woodgett J.R., Boothby M.R., and Ohashi P.S. NF-kappaB couples protein kinase B/Akt signaling to distinct survival pathways and the regulation of lymphocyte homeostasis in vivo. J. Immunol. 175 (2005) 3790-3799
25. Jurado J.O., Alvarez I.B., Pasquinelli V., Martinez G.J., Quiroga M.F., Abbate E., Musella R.M., Chuluyan H.E., and Garcia V.E. Programmed death PD-1: PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. J. Immunol. 181 (2008) 116-125
26. Keir M.E., Butte M.J., Freeman G.J., and Sharpe A.H. PD-1 and its ligands in tolerance and immunity. Annu. Rev. Immunol. 26 (2008) 677-704
27. Keir M.E., Latchman Y.E., Freeman G.J., and Sharpe A.H. Programmed death-1 PD-1:PD-ligand 1 interactions inhibit TCR-mediated positive selection of thymocytes. J. Immunol. 175 (2005) 7372-7379
28. Kim Y.S., Park G.B., Lee H.Y., Song H., Choi I.H., Lee W.J., and Hur D.Y. Cross-linking of B7-H1 on EBV-transformed B cells induces apoptosis through reactive oxygen species production, JNK signaling activation, and fasL expression. J. Immunol. 181 (2008) 6158-6169
29. Kitazawa Y., Fujino M., Wang Q.X., Kimura H., Azumi M., Kumo M., Abe R., and Li X.K. Involvement of the programmed death-1/programmed death-1 ligand pathway in CD4+CD25+ regulatory T-cell activity to suppress alloimmune responses. Transplantation 83 (2007) 774-782
30. Kroner A., Mehling M., Hemmer B., Rieckmann P., Toyka K.V., Maurer M., and Wiendl H. A PD-1 polymorphism is associated with disease progression in multiple sclerosis. Ann. Neurol. 58 (2005) 50-57
31. Lee J.H., Joo Y.D., Yim D., Lee R., Ostrander E.A., Loretz C., Little M.T., Storb R., and Kuhr C.S. Molecular cloning and characterization of canine ICOS. Genomics 84 (2004) 730-736
32. Lee J., Zhuang Y., Wei X., Shang F.J., Wang J.P., Zhang Y., Liu X.T., Yang Y.H., Liu L., and Zheng Q. Contributions of PD-1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis. J. Mol. Cell. Cardiol. 46 (2009) 169-176
33. Liang S.C., Latchman Y.E., Buhlmann J.E., Tomczak M.F., Horwitz B.H., Freeman G.J., and Sharpe A.H. Regulation of PD-1, PD-L1, and PD-L2 expression during normal and autoimmune responses. Eur. J. Immunol. 33 (2003) 2706-2716
34. Matsumoto K., Inoue H., Nakano T., Tsuda M., Yoshiura Y., Fukuyama S., Tsushima F., Hoshino T., Aizawa H., et al. B7-DC regulates asthmatic response by an IFN-γ-dependent mechanism. J. Immunol. 172 (2004) 2530-2541
35. New D.C., Wu K., Kwok A.W., and Wong Y.H. G protein-coupled receptor-induced Akt activity in cellular proliferation and apoptosis. FEBS J. 274 (2007) 6025-6036
36. Nielsen C., Hansen D., Husby S., Jacobsen B.B., and Lillevang S.T. Association of a putative regulatory polymorphism in the PD-1 gene with susceptibility to type 1 diabetes. Tissue Antigens 62 (2003) 492-497
37. Nielsen C., Laustrup H., Voss A., Junker P., Husby S., and Lillevang S.T. A putative regulatory polymorphism in PD-1 is associated with nephropathy in a population-based cohort of systemic lupus erythematosus patients. Lupus 13 (2004) 510-516
38. Nielsen C., Ohm-Laursen L., Barington T., Husby S., and Lillevang S.T. Alternative splice variants of the human PD-1 gene. Cell. Immunol. 235 (2005) 109-116
39. - thymocytes. Int. Immunol. 8 (1996) 773-780
40. Nishimura H., Nose M., Hiai H., Minato N., and Honjo T. Development of lupus-like autoimmune diseases by disruption of the PD-1 gene encoding an ITIM motif-carrying immunoreceptor. Immunity 11 (1999) 141-151
41. Nishimura H., Okazaki T., Tanaka Y., Nakatani K., Hara M., Matsumori A., Sasayama S., Mizoguchi A., Hiai H., Minato N., and Honjo T. Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice. Science 291 (2001) 319-322
42. Okazaki T., and Honjo T. PD-1 and PD-1 ligands: from discovery to clinical application. Int. Immunol. 19 (2007) 813-824
43. Parsons K.R., Young J.R., Collins B.A., and Howard C.J. Cattle CTLA-4, CD28 and chicken CD28 bind CD86: MYPPPY is not conserved in cattle CD28. Immunogenetics 43 (1996) 388-391
44. Parsons K.R., and Howard C.J. Cloning of cattle CD80. Immunogenetics 49 (1999) 231-234
45. Pentcheva-Hoang T., Chen L., Pardoll D.M., and Allison J.P. Programmed death-1 concentration at the immunological synapse is determined by ligand affinity and availability. Proc. Natl. Acad. Sci. U.S.A. 104 (2007) 17765-17770
46. Prokunina L., Padyukov L., Bennet A., de Faire U., Wiman B., Prince J., Alfredsson L., Klareskog L., and Alarcon-Riquelme M. Association of the PD-1.3A allele of the PDCD1 gene in patients with rheumatoid arthritis negative for rheumatoid factor and the shared epitope. Arthritis Rheum. 50 (2004) 1770-1773
47. Radhakrishnan S., Nguyen L.T., Ciric B., Van Keulen V.P., and Pease L.R. B7-DC/PD-L2 cross-linking induces NF-kappa B-dependent protection of dendritic cells from cell death. J. Immunol. 178 (2007) 1426-1432
48. Reynoso E.D., Elpek K.G., Francisco L., Bronson R., Bellemare-Pelletier A., Sharp A.H., Freeman G.J., and Turley S.J. Intestinal tolerance is converted to autoimmune enteritis upon PD-1 ligand blockade. J. Immunol. 182 (2009) 2102-2112
49. Salama A.D., Chitnis T., Imitola J., Ansari M.J., Akiba H., Tushima F., Azuma M., Yagita H., Sayegh M.H., and Khoury S.J. Critical role of the programmed death-1 (PD-1) pathway in regulation of experimental autoimmune encephalomyelitis. J. Exp. Med. 198 (2003) 71-78
50. Sandner S.E., Clarkson M.R., Salama A.D., Sanchez-Fueyo A., Domenig C., Habicht A., Najafian N., Yagita H., Azuma M., Turka L.A., and Sayegh M.H. Role of the programmed death-1 pathway in regulation of alloimmune responses in vivo. J. Immunol. 174 (2005) 3408-3415
51. Sheppard K.A., Fitz L.J., Lee J.M., Benander C., George J.A., Wooters J., Oiu Y., Jussif J.M., Carter L.L., et al. PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. FEBS Lett. 574 (2004) 37-41
52. Shimauchi T., Kabashima K., Nakashima D., Sugita K., Yamada Y., Hino R., and Tokura Y. Augmented expression of programmed death-1 in both neoplastic and non-neoplastic CD4+ T-cells in adult T-cell leukemia/lymphoma. Int. J. Cancer 121 (2007) 2585-2590
53. Shin I.S., Choi E.W., Chung J.Y., Hwang C.Y., Lee C.W., and Youn H.Y. Cloning, expression and bioassay of canine CTLA4Ig. Vet. Immunol. Immunopathol. 118 (2007) 12-18
54. Taglauer E.S., Holets L.M., Slusser J.G., and Petroff M.G. Expression of PD-1 on T cell subpopulations at the maternal-fetal interface. J. Reprod. Immunol. 71 (2006) 151-1151
55. Taylor P.A., Lees C.J., Fournier S., Allison J.P., Sharpe A.H., and Blazar B.R. B7 expression on T cells down-regulates immune responses through CTLA-4 ligation via T-T interactions. J. Immunol. 172 (2004) 34-39
56. Terzo E.A., de Villarreal M.P., Mick V., Muñoz F., Amorena B., de Andrés D., and Pérez de la Lastra J.M. Molecular cloning of multiple forms of the ovine B7-2 (CD86) costimulatory molecule. Vet. Immunol. Immunopathol. 114 (2006) 149-158
57. Thompson R.H., Dong H., and Kwon E.D. Implications of B7-H1 expression in clear cell carcinoma of the kidney for prognostication and therapy. Clin. Cancer Res. 13 2 Pt 2 (2007) 709s-715s
58. Trautmann L., Janbazian L., Chomont N., Said E.A., Gimmig S., Bessette B., Boulassel M.R., Delwart E., Sepulveda H., et al. Upregulation of PD-1 expression on HIV-specific CD8+ T cells leads to reversible immune dysfunction. Nat. Med. 12 (2006) 1198-1202
59. Usui Y., Okunuki Y., Hattori T., Kezuka T., Keino H., Ebihara N., Sugita S., Usui M., Goto H., and Takeuchi M. Functional expression of B7H1 on retinal pigment epithelial cells. Exp. Eye Res. 86 (2008) 52-59
60. Yang S., Sellins K.S., Powell T., Stoneman E., and Sim G.K. Novel transcripts encoding secreted forms of feline CD80 and CD86 costimulatory molecules. Vet. Immunol. Immunopathol. 81 (2001) 15-21
61. Yang J., Popoola J., Khandwala S., Vadivel N., Vanguri V., Yuan X., Dada S., Guleria I., Tian C., Ansari M.J., Shin T., Yagita H., Azuma M., Sayegh M.H., and Chandraker A. Critical role of donor tissue expression of programmed death ligand-1 in regulating cardiac allograft rejection and vasculopathy. Circulation 117 (2008) 660-669
62. Yao Z.Q., King E., Prayther D., Yin D., and Moorman J. T cell dysfunction by hepatitis C virus core protein involves PD-1/PDL-1 signaling. Viral Immunol. 20 (2007) 276-287
63. Zhang X., and Strome S.E. B7-H1-targeted immunotherapy for head and neck cancer. Expert Opin. Biol. Ther. 4 (2004) 1577-1583
64. Zhu B., Guleria I., Khosroshahi A., Chitnis T., Imotola J., Azuma M., Yagita H., Sayegh M.H., and Khoury S.J. Differential role of programmed death-ligand 1 and programmed death-ligand 2 in regulating the susceptibility and chronic progression of experimental autoimmune encephalomyelitis. J. Immunol. 176 (2006) 3480-3489